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Abstract:
This paper discusses the impact of schizophrenia on American society and advocates for health care reform to
address the lack of access by the mentally ill to a class of innovative drugs, called “atypical anti-psychotics.”
Atypical anti-psychotic drugs, including clozapine, risperidone and olanzapine are crucial for the treatment
of both the positive and negative symptoms of schizophrenia and should be made available as ﬁrst-line
treatments for schizophrenics. Current health care policies and reforms provide facially attractive beneﬁts,
but lack signiﬁcant practical beneﬁts, resulting in obstacles to access to these life-changing medications.
Health care reforms providing adequate reimbursement for these medications, and thereby opening access
to them on a ﬁrst-line basis, would in fact relieve ﬁnancial pressures on our health care system instead of
creating further strain on scarce resources by reducing funds spent on hospitalization and other medical
resources.
1Introduction
Mental health research and pharmaceutical innovation have developed a class of drugs referred to as “atypical
antipsychotics,” which are used for the treatment of severe schizophrenics who are considered treatment-
resistant to traditional or conventional antipsychotic medications, or who experience side-eﬀects severe
enough to require that the patient discontinue use of conventional antipsychotics. These atypical antipsy-
chotics are tremendously eﬀective in combating the symptoms of schizophrenia while avoiding the severe
side-eﬀects often experienced through treatment with conventional antipsychotics. Despite the existence
and availability of such drugs on the pharmaceutical market, both public and private mental health care
policy in the United States create barriers to access to these treatments. Stigma and prejudice associated
with schizophrenia, and concerns about the high cost of the atypicals stand out as the primary culprits for
the inequitable distribution of resources for mental health care as compared to resources devoted to the
treatment of more visible and politically or socially palatable “wholly physiological” illnesses.
Access to atypical antipsychotic medications as ﬁrst-line medications is crucial to the treatment of schizophren-
ics for a number of reasons. First of all, the conventional or traditional antipsychotics carry with them severe
and potentially irreversible side-eﬀects that greatly impact the quality of a schizophrenic patient’s life. Sec-
ondly, the side-eﬀects of the conventional antipsychotics lead to the disturbing consequence of poor patient
compliance with treatment, thereby increasing the risk of harmful relapse episodes by patients. Third, the
traditional treatments do not relieve the negative symptoms of the disorder, resulting in the reduction of
delusions and hallucinations, but doing little or nothing to correct the anti-social behavior exhibited by
schizophrenics. This anti-social behavior, which is largely responsible for the inability of schizophrenics to
function in their communities, must be remedied in order to reintegrate individuals suﬀering from schizophre-
nia into society as self-suﬃcient, functioning members of their communities.
As the country increases its awareness of the consequences of schizophrenia on its citizens as well as on
2society as a whole, reform of current health care policy will be necessary in order to address the resource
needs of the long-neglected population of schizophrenics. Though some eﬀorts have been made to equalize
beneﬁts provided to patients suﬀering from mental health disorders versus what many claim are distinctly
physiological disorders, the reforms made to date have been largely symbolic and ineﬀective in practice.
Signiﬁcantly, the plea for access to necessary atypical antipsychotic treatments diﬀers from the suggestion
that these medications should become freely available to every schizophrenic or that the prescription of
such medications should become routinized so as to make access similar to that of any other prescription
medication. Reform of current policy toward distribution of these medications should merely facilitate
physician-patient independence to determine which treatments are most promising for each individual pa-
tient. Oversight of the distribution of these drugs, and their marketing should certainly be permitted and
indeed, encouraged or mandated government regulation to ensure that proper safety precautions are taken.
The “facilitation” of physician-patient interactions and of physician and patient independence does not,
however, come easily. Systemic structures, including managed care, have greatly impacted the ability of
physicians to make independent decisions regarding the care of their patients. In the area of mental health
care, this fact rings especially true, and in the narrower area of atypical antipsychotic treatments, even truer
still. The high cost of atypical antipsychotic medications, coupled with their monitoring requirements – in
some cases mandating weekly blood tests to ensure the maintenance of the patient’s blood cell counts1 –
make these medications some of the most expensive on the pharmaceutical market. However, cost concerns
may and should be addressed through means other than by barring access to these vital treatments.
The increased availability and access to atypical antipsychotic treatments will beneﬁt not only the schizophrenic
community, but will also beneﬁt society as a whole by allowing a large population of persons to reintegrate
1novartis pharmaceuticals corporation, clozaril prescribing information (2001) at 5.
3with society by securing employment and functioning as otherwise productive members of their communities
instead of representing a drain on health care and other welfare resources. “[N]early 30 percent ($19 billion)
of schizophrenia’s costs involves direct treatment and the rest is absorbed by other factors – lost time from
work for patients and care givers, social services and criminal justice resources...[S]chizophrenia aﬀects one
percent of the population, accounts for a fourth of all mental health costs and takes up one in three psychi-
atric hospital beds. Since most schizophrenia patients are never able to work, they must be supported for
life by Medicaid and other forms of public assistance.”2 Clearly, factors other than the price of the drugs
alone enter into the equation of determining the cost-eﬀectiveness of providing appropriate medications for
the treatment of schizophrenia. The seemingly exorbitant costs of the atypical antipsychotic drugs needed
to eﬀectively treat schizophrenia may be more than recouped through the eﬀective reintegration of those
suﬀering from schizophrenia into society, ultimately resulting in a net conservation of resources.
Furthermore, it has been suggested that the high price of atypical antipsychotic treatments may more ap-
propriately be attributed to the premium placed on such drugs due to our tort laws and the increasingly
litigious nature of American society. The combination of the two phenomena creates an incentive for drug
manufacturers to place barriers to access in the form of increased costs in order to build in the price of
possible tort liability for these eﬀective but high-risk drugs.
Some combination of mental health parity laws requiring a non-discrimination standard of providing health
care beneﬁts, and the relaxing of tort liability for drug manufacturers who produce beneﬁcial, yet high risk,
medications would beneﬁt patients in desperate need of these treatments. Such new policies may provide a
much needed incentive to drug manufacturers to develop still other drugs that may be even more eﬀective
in treating schizophrenic patients. Likewise, a relaxing of tort liability with regard to the use of the atypical
antipsychotics would reduce the incentive for physicians to treat schizophrenic patients with inferior, con-
2The Schizophrenia Homepage, U.S. Health Oﬃcial Puts Schizophrenia Costs at $65 Billion, (May 9, 1996) (summarizing
statements made by Richard Wyatt, M.D., chief of neuropsychiatry, National Institutes of Mental Health, made at an annual
meeting of the American Psychiatric Association) (emphasis added) at http://www.schizophrenia.com/news/costs1.html.
4ventional antipsychotics for the purpose of avoiding medical malpractice liability. Instead, physicians would
be permitted to use objective criteria to make informed decisions as to which treatment would provide the
greatest beneﬁts to a given patient. Our health care laws should facilitate physician-patient interactions
when dealing with mental illnesses and not impede physician judgment through managed care, tort liability,
or cost concerns that lie outside the realm of concern for the patient’s ultimate well-being.
A. The Problem of Schizophrenia
I. Background Information
Schizophrenia presents a serious health care problem in the United States and worldwide. The National
Institute of Mental Health estimates that about one in one hundred people in the United States will develop
schizophrenia during his or her lifetime.3 Among developed nations, schizophrenia, along with other mental
disorders, has become one of the leading causes of disability.4 In addition to the symptoms the disorder
directly imposes on its victims, other correlating conditions and factors jeopardize the lives of schizophrenic
patients. Seven to ten percent of schizophrenic patients are estimated to commit suicide.5 Schizophrenics
also suﬀer from natural diseases and physiological ailments such as cardiovascular illness at rates that exceed
those of the average population.6 Thus, the illness carries with it deﬁnite physiological consequences as well
as the less tangible “purely mental” symptoms of the disorder. Moreover, a signiﬁcant body of evidence
suggests that schizophrenia is a biological disorder or disease of the brain.7 This new information casts
3Margie Patlak, Schizophrenia: Real Lives Ravaged by Imaginary Terror, fda consumer magazine Sept. - Oct. 1997,
available at http://www.fda.gov/fdac/features/1997/697 schiz.html.
4Michael D. Brophy, Emerging Medical-Legal Issues in the Prescriber-Patient, 18 No. 8 Med. Malpractice L. & Strategy
4, (2001).
5Milt Freudenheim, Seeking Safer Treatments for Schizophrenia, N.Y. Times, Jan. 15, 1992, at D5. See also Brophy supra
note 4.
6Transcript of Food and Drug Administration Center for Drug Evaluation and Research Psychopharmacologic Drugs Advi-
sory Committee, July 19, 2000 at 22. [ Hereinafter Advisory Committee Transcript ].
7Richard E. Gardner, III, Mind Over Matter?: The Historical Search for Meaningful Parity Between Mental and Physical
Health Care Coverage, 49 Emory L.J. 675 ,683 (2000) (“Though studies have shown varied results, most scientists agree that
schizophrenics have lighter than normal brains with enlarged ventricles. The schizophrenic’s brain also typically has smaller
frontal lobes or a reduction in neurons in the frontal lobes, and is characterized by more of a random neural organization than
a normal brain’s ‘consistent parallel orientation.’ These ﬁndings are reﬂected in the statement by Dr. E. Fuller Torrey, who
5suspicion on the argument that disparate coverage provisions often encountered in health care plans are
justiﬁed because of the entirely “mental” nature of schizophrenia as compared to other physical disorders.
Current mental health care policy should address the need for eﬀective treatment of this debilitating and
life-threatening disorder. The one percent ﬁgure of people likely to develop schizophrenia stands to increase
in the near future, rendering the problem of lack of adequate treatment options an even greater problem.
Demographic changes in our country increase the potential for incidence of the disorder as a percentage
of the general population. As the average life expectancy grows and the elderly become an increasingly
numerous population, health care policy should address the problem of disability due to mental illness,
especially in those individuals over 65 years of age. Conditions such as schizophrenia, among others, will
pose particular problems for this group.8 If left unrecognized and/or untreated, late-life schizophrenia may
severely impair or even be fatal to those it aﬄicts.9 Thus, barriers to access to treatment established by
government regulation or managed care pose a particular threat to the welfare of schizophrenic patients.
“There is some literature which suggests that people with schizophrenia do not appreciate that they have
the condition about 50 percent of the time. So now we have a person who may not appreciate that their
perception of reality does not jive with other people, and we introduce limitations on how well they access
services...There is little surprise, then, that we result in a situation where people delay treatment, which
worsens the course of their illness, and they do not have access to treatment as soon as possible.”10 Reform
of existing mental health care may address the problem of treatment delays that may prove seriously or even
concluded that the ‘evidence is now overwhelming that the brains of persons who have schizophrenia are, as a group, diﬀerent
from brains of persons who do not have this disease.”’)
8Medicare Mental Health Modernization Act of 2001, H.R. 1522/S. 690 107th Cong. 1st session (2001) (currently referred
to Subcommittee on Health).
9Id. at 3.
10Statement by Dr. Kenneth Duckworth, deputy commissioner, Massachusetts Department of Mental Health, Boston, MA,
before Hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, 106th Congress, 2nd Session
on Examining Mental Health parity issues, including S. 796, to provide for full parity with respect to health insurance coverage
for certain severe biologically-based mental illnesses and to prohibit limits on the number of mental illness-related hospital days
and outpatient visits that are covered for all mental illnesses, May 18, 2000, p. 87.
6permanently damaging to the lives of suﬀerers of this disorder.
The fact that full recovery from schizophrenia rarely occurs underscores the need for the availability of safe
and eﬀective drugs to treat the symptoms of the disease. The incidence of schizophrenia has the potential
to signiﬁcantly impact United States health care policy. One ﬁgure estimates that approximately 3 million
people in the United States suﬀer from schizophrenia.11 In addition, the disorder accounts for 25 percent of all
hospital bed days in the United States!12 Moreover, due to its chronic and debilitating nature, schizophrenia
accounts for approximately 2.5 percent of all United States health care costs, 10 percent of all permanently
and totally disabled citizens, and 20 to 30 percent of the homeless population.13 Lastly, evidence shows that
schizophrenics, due to a combination of the above factors, including under-treatment of the disorder, have
an average 20 percent shorter life span than persons in the general population.14
Development of schizophrenia typically appears in adolescence or in the twenties in men and in the twenties or
early thirties in women. Children rarely demonstrate schizophrenic symptoms. Indeed, many schizophrenics
exhibit entirely normal behavior during childhood.15 The disease is characterized by a series of symptoms,
which include those generally referred to as “positive symptoms” (delusions and hallucinations), “negative
symptoms” (anti-social behavior and loss of emotional response), and “cognitive symptoms” (disordered
thought and attention deﬁcits).16 Common manifestations of hallucinations in schizophrenics include the
hearing of voices that no one else can hear that tell a patient what to do, describe what the patient is doing,
11Advisory Committee Transcript supra note 6 at 21.
12Id. at 21-22.
13Anthony F. Lehman, Quality of Care In Mental Health: The Case of Schizophrenia; New therapies show great promise
in treating persons with schizophrenia. The challenge is to get the treatment to the patient, Health Affairs (The People-
To-People Health Foundation, Inc.) (1999) (citing A. Rupp and S. Keith, The Costs of Schizophrenia: Assessing the Burden,
Psychiatrics Clinics of North America 16, No. 2 (1993): 413-23).
14Advisory Committee Transcript supra note 6 at 27.
15Patlak supra note 3.
16Cortex Pharmaceuticals, Inc., Annual Report 6-7 (2000). http://www.cortexpharm.com/pdfs/CORX10KSB00.pdf.
7warn the patient of danger, or carry on conversations with the patient. Delusions of persecution or grandeur
are also common among schizophrenics.17
Generally speaking, a diagnosis of schizophrenia requires the demonstration by a patient of two or more of
the above symptoms during a one-month period.18 Furthermore, a substantial inability to work or social-
ize for at least six months would indicate to a physician the strong possibility of schizophrenia in the patient.19
II.
Conventional Antipsychotic Treatments for Schizophrenia and the Need for Access to Atypical Antipsychotics
Initially, schizophrenics turned to treatment for their positive symptoms in drugs generally characterized as
“neuroleptics” or “conventional antipsychotics,” which functioned chemically by blocking the binding sites
for the neurotransmitter, dopamine.20 These drugs were largely developed in the 1950s and 1960s.21 The
ﬁrst conventional antipsychotic, chlorpromazine (marketed under the name “Thorazine”), began a period
that included the development of more than a dozen similar drugs including haloperidol (marketed under the
name “Haldol”), thioridazine (marketed as “Mellaril”), loxapine (marketed under the name “Loxatane”),
and molindone (marketed as “Moban”).22 The chemical process of these medications causes the
These conventional antipsychotics continue to be used today. These drugs made the signiﬁcant contributions
of treating the positive symptoms of the disease, as well as reducing the need for chronic hospitalization
17Patlak supra note 3.
18Diagnostic and Statistical Manual of Mental Disorders, Revised (DSM III-R) (American Psychiatric Press, Wash-
ington D.C., 3d ed. 1987).
19Patlak supra note 3. One should note, however, that schizophrenic symptoms might develop due to the use of drugs such
as phencyclidine hydrochloride (PCP) or chronic high doses of amphetamines. A physician would rule out such drugs as the
cause of such symptoms before making a ﬁrm diagnosis of schizophrenia for the patient.
20Patlak supra note 3.
21Cortex Pharmaceuticals, Inc., supra note 16 at 7.
22Patlak supra note 3.
8of schizophrenics. However, the conventional antipsychotics carry with them severe and sometimes life-
threatening side-eﬀects. Common side-eﬀects of the conventional antipsychotics include “extrapyramidal
signs,” which appear as uncontrollable muscle spasms or tremors resembling symptoms commonly observed
in those with Parkinson’s disease.23 These side-eﬀects lead to poor quality of life for patients using the drugs,
and cause the additional problematic result of poor patient compliance with continuing treatment with their
medications. “Given [the] many reports of how normals react to single low doses of neuroleptics, one may
wonder how it is that so many schizophrenic patients can tolerate them at all.”24
Other largely dose-dependent side-eﬀects of conventional antipsychotics include drowsiness, restlessness,
cramps, dizziness, stiﬀness of the limbs, dry mouth, impotence, menstrual irregularities, or blurring of vi-
sion.25 Moreover, long-term use of these drugs may cause a condition known as “tardive dyskinesia,” which
is a disorder in which the patient suﬀers involuntary movements or tics.26 The greater the period of treat-
ment with these drugs, the greater the risk of developing tardive dyskinesia. More than 25 percent of
schizophrenic patients taking conventional antipsychotics for over ﬁve years develop the disorder.27 Tardive
dyskinesia occurs in up to 70 percent of high-risk schizophrenic patients such as the elderly, making the
use of traditional antipsychotics a clear risk for treating such populations.28 And, as noted earlier, due to
demographic changes, this group stands to increase as a percentage of the general population. The risk of
developing tardive dyskinesia and the likelihood that it will become irreversible increases as the duration
of treatment and dosages increase.29 Moreover, there is no known treatment for established cases of the
disorder aside from withdrawal from the use of the responsible drug.30
23nat’l institute of mental health, Improving Treatments, Preventing Relapse: Atypical Antipsychotic Medications (June
1, 2001) at http://www.nimh.nih.gov/sciadvances/Atypical.cfm.
24Weidan, Shaw & Mann, Causes of Neuroleptic Noncompliance, 16 Psychiatric Annals 571 (1986). Neuroleptic is another
name for antipsychotic drugs.
25Patlak supra note 3.
26Patlak supra note 3.
27Patlak supra note 3.
28Advisory Committee Transcript supra note 6 at 23.
29Novartis, supra note 1 at 9.
30Id.
9The conventional antipsychotics therefore have severe limitations for those who experience side-eﬀects with
their use. Signiﬁcantly, these drugs also do not alleviate the symptoms of cognitive dysfunction, apathy or
other negative symptoms that are largely responsible for the social disability associated with schizophre-
nia.31 Cognitive impairment, which may aﬀect attention, memory, and executive function, can present
“insurmountable social and vocational obstacles to patients” suﬀering from schizophrenia.32 Thus, the tra-
ditional treatments are limited in their ability to solve for the considerable problem of many schizophrenics’
inability to reintegrate into society and regain independence and control of their lives.
The use of atypical antipsychotic treatments, however, “provides maximum control of both positive and neg-
ative symptoms, limits cognitive impairment, and gets patients back to school and to work quickly, so that
they don’t become dropouts and loners.”33 Prior to the availability of atypical antipsychotic treatments,
90 percent of patients taking the conventional antipsychotics possessed functional disabilities that hindered
them from working. The atypical antipsychotics give many the option to work for the ﬁrst time since the
onset of their conditions.34
III. Atypical Antipsychotics: The Need for Them and FDA Regulation
The atypical antipsychotics emerged in the 1960s, when they received the name “atypical” because “they
could be administered in doses that alleviated positive symptoms without causing the neurological side-eﬀects
associated with the conventional agents.”35 Atypical antipsychotics, like their predecessor conventional an-
tipsychotics, also aﬀect the neurotransmitter dopamine, but work further to aﬀect the neurotransmitter
serotonin. The atypical antipsychotics, speciﬁcally, decreased the incidence of extrapyramidal symptoms,
diminished hyperprolactinemia,36 demonstrated superior eﬃcacy in refractory schizophrenia, lessened the
31Brophy supra note 4.
32Brendan Ross & Leigh Ann Ramsey, Novel Antipsychotic Drugs in the Management of Schizophrenia, 145 Drug Topics
No. 9, 75 (2001).
33Lynne Lamberg, New Medications Aid Cognition in Schizophrenia, 280 J. Am. Med. Ass’n No. 11, (1998).
34Id.
35Brophy, supra note 4. (quoting Douglas Mossman, M.D., & Douglas S. Lehrer, M.D., Conventional and Atypical Antipsy-
chotics and the Evolving Standard of Care, 51 Psychiatric Services, No. 12 (2000).
36Hyperprolactinemia is a pituitary disorder characterized by an excess of the hormone pro-
10hallucinations and bizarre behavior of patients, and had the substantial added beneﬁt of relieving negative
symptoms of the disorder37 (though the FDA has not yet determined the veracity of the superiority of the
atypical antipsychotics in treating negative symptoms).38
Three major atypical antipsychotics appeared in the 1960s to 1980s.39 Clozapine was the ﬁrst synthesized in
1960, and by the late 1960s entered distribution in European markets.40 Clozapine was initially developed
and patented by Sandoz Ltd. of Switzerland, and marketed in the United States by the subsidiary Sandoz
Pharmaceutical Corp, under the popular brand name “Clozaril.”41
The atypical antipsychotics have been widely adopted in North America and account for three-fourths of
all antipsychotic prescriptions.42 They are more expensive than the traditional antipsychotics, but the cost
is largely accepted as justiﬁed by advocates for the treatments because they are believed to be more eﬀec-
tive and better tolerated.43 Substantial evidence suggests clozapine’s eﬃcacy in patients who have received
unsuccessful or ineﬀective treatment through the use of conventional neuroleptics.44 About one-third to one-
half of those who take clozapine respond positively to the drug.45 During clinical trials, clozapine reduced
psychotic symptoms in 30 percent46 to 65 percent47 of the patients treated.
lactin. Pituitary Network Association, Hyperprolactinemia and Prolactinomas, (2001) at
http://www.pituitary.com/PituitaryNewsUpdates/PituitaryNews/may4/HyperprolactinemiaProlactinomasFactSheet.
37Ross & Ramsey supra note 32.
38Patlak supra note 3.
39Cortex Pharmaceuticals, Inc., supra note 16 at 7.
40Judy Folkenberg, New Schizophrenia Drug: Balancing Hope with Safety, FDA Consumer Magazine, (June 1990), available
at http://www.fda.gov/bbs/topics/CONSUMER/CON00055.html.
41Robert N. Swidler, Medical Innovations and Ethics: A State Government Perspective, 57 Alb. L. Rev. 655, 668 (1994).
See also Carl Salzman, Mandatory Monitoring for Side-eﬀects: The “Bundling” of Clozapine, 323 New Eng. J. Med 827,
827 (1990).
42Some clinicians, however, continue to prescribe the conventional antipsychotics, either because of their comfort level with
using the drugs and/or their belief that the drugs truly are superior to the newer antipsychotics. Brophy supra note 4.
43Brophy supra note 4.
44Ramsey & Ross supra note 32 (“In one trial of treatment-resistant patients, clozapine therapy demonstrated a 30% response
rate after six weeks, compared with a 4% rate for a conventional drug. In longer-term studies, approximately 70% of such patients
received signiﬁcant beneﬁts from Clozapine use. Clozapine produced greater improvements in negative or deﬁcit symptoms,
such as emotional withdrawal, blunted aﬀect, and motor retardation, as well. Cognitive function improved in responders, but
beneﬁts were modest.”).
45Catherine E. Blackburn, New Directions in Mental Health Advocacy? Clozapine and the Right of Medical Self-
Determination, 14 Mental & Physical Disability L. Rep. 453, 453 (1990).
46Id. at 453 (citing Honigfeld, G. & Patin, J., A Two-Year Clinical and Economic Follow-Up of Patients on Clozapine, 41
Hosp. & Community Psychiatry 882, 883 (1990)).
47Id. (citing Naber & Hippius, The European Experience with Use of Clozapine, 41 Hosp. & Community Psychiatry 886,
11The clinical testing of clozapine showed a virtual absence of extrapyramidal symptoms. Clozapine’s weak
dopamine blocking eﬀect as compared to the conventional antipsychotics, may explain its lesser side-eﬀects.
Furthermore, no reports (as of June of 2001) of tardive dyskinesia have been directly attributable to the
use of clozapine.48 Thus, testing of clozapine suggests that its use may avoid the risk of developing tardive
dyskinesia, a potentially irreversible consequence of treatment with the conventional antipsychotics.
Clozapine does, however, possess its own unique set of risks and side-eﬀects. The FDA halted the initial
clinical trial of clozapine in the 1970s due, primarily, to the risk of severe side-eﬀects. In 1975, post-market
reports from Finland informed the United States that eight schizophrenic patients had died from complica-
tions associated with agranulocytosis,49 a fatal blood disorder50 in which the patient’s bone marrow ceases
to produce white blood cells, which are necessary in ﬁghting infection.51 The drug was subsequently re-
marketed in Europe after coupling it with a monitoring program.52
Agranulocytosis occurs in an estimated 1.3 percent of patients who have used the drug for a period of one
year.53 To give some perspective on the relative risk of this disorder due to the use of clozapine, agranu-
locytosis occurs over 100 times more often with clozapine than with a conventional antipsychotic, such as
chlorpromazine.54 As of December 31, 1989, 32 percent of the 149 worldwide reported cases of agranulo-
cytosis resulted in death. However, few of these deaths occurred after 1977, when the eﬀects of clozapine
on inducing agranulocytosis became more widespread and at which time stricter monitoring of white blood
cell counts became more widely practiced.55 Still, “it is unknown at present what the case fatality rate will
887, 888 (1990)).
48Novartis supra note 1at 9.
49Chris Spolar, New Schizophrenia Drug Arouses Furor Over Cost; Debate Focuses on Control of Monitoring System. Wash.
Post, July 31, 1990, at Z7.
50A blood disorder characterized by a reduction in white blood cells, which leaves the patient vulnerable to infection. A
common cold could be fatal to a patient with this disorder. Folkenberg supra note 40.
51Blackburn supra note 45 at 454.
52Spolar supra note 49.
53Novartis supra note 1at 4.
54Blackburn supra note 45 at 454.
55Novartis supra note 1at 4.
12be for Clozaril (clozapine) induced agranulocytosis, despite strict adherence to the required frequency of
monitoring.”56
Vigilant monitoring of patients and early detection of agranulocytosis remains the key to preventing fatal
results.57 In clinical trials, patients recovered from the disorder when they ceased taking the medication.58
However, if bone marrow depression is undetected at an early stage, the disorder becomes irreversible and
fatal.59
Furthermore, clozapine causes a seemingly dose-dependent risk of seizures, aﬀecting approximately ﬁve per-
cent of users during clinical testing who had taken the drug for one year.60 The product literature advises
against the prescription of clozapine to patients with a history of seizures or “other predisposing factors.”
Furthermore, patients using the drug should not engage in activities that might become dangerous should a
sudden loss of consciousness occur, such as driving, the operation of complex machinery, swimming, etc.61
Other conditions possibly related to clozapine use (though their relationship to the drug is less certain than
those of seizures and agranulocytosis) are various adverse cardiovascular and respiratory eﬀects including
tachycardia, hypotension, and neuroleptic malignant syndrome.62
Despite the risks associated with the use of clozapine, the drug was reintroduced in the 1980s when the
FDA approved it for compassionate reasons so that it could be used in patients who were unable to undergo
treatment with traditional neuroleptics.63 The FDA approved clozapine for use by those people who had
tried, but had experienced unsatisfactory results (such as lack of eﬃcacy or signiﬁcant side-eﬀects) with
conventional antipsychotics. Current product literature for Clozaril states that the drug has been approved
56Id.
57No deaths had occurred in the United States as a result of use of Clozapine (as of 1987) due to the reversible nature of the
disorder with early detection. New Drug is Said to Help Severe Schizophrenics, N.Y Times, May 15, 1987 at B12.
58Folkenberg supra note 40.
59Blackburn supra note 45 at 454.
60Novartis supra note 1 at 7.
61Novartis supra note 1 at 7.
62Novartis supra note 1 at 8. Due to the limited information on the eﬀects of clozapine on the occurrence of these conditions,
they will not be discussed in further detail in this piece.
63Cortex Pharmaceuticals, Inc., supra note 16 at 7; Folkenberg supra note 40.
13for “the management of severely ill schizophrenic patients who fail to respond adequately to standard anti-
psychotic drug treatment.”64 As for seizures, simply lowering the dosage or treating with anti-convulsant
drugs typically relieves the problem.65
Due to the dangers associated with the use of clozapine, careful monitoring must accompany treatment
with the drug. Patients who do not demonstrate an acceptable level of clinical response over an extended
period of time should cease treatment with clozapine.66 The product literature recommends that physicians
considering the use of clozapine on a patient ﬁrst perform two trials - “each with a diﬀerent standard anti-
psychotic drug product, at an adequate dose, and for an adequate duration”- before making a determination
that conventional antipsychotics are insuﬃcient for treatment of the patient.67
This recommendation as stated in the product literature demonstrates one of the ways in which atypicals
are currently reserved for second-line, instead of ﬁrst-line treatments. As discussed later in this essay, such
a requirement creates ineﬃciencies in resource expenditure and more importantly, places patients at serious
risk of developing harmful conditions attributed to the use of the conventional antipsychotics. Physicians
should be given the liberty to treat patients on a case-by-case basis, choosing whichever treatments the
physician and patient decide would be most advantageous to the health of the patient. However, current
health care policy and even reforms tend to reserve reimbursement for approved uses, such as those stated
in the product literature, which thereby limit the options available to patients who lack funding suﬃcient to
independently cover the price of medication.
From the beginning, clozapine was eyed with suspicion due to the hazards accompanying the drug. However,
the incredible beneﬁts derived from the use of it and other atypicals have slowly opened pathways to obtain-
64Blackburn, supra note 45 at 453 (quoting Product Literature supplied with Clozaril, the trade name for clozapine, manu-
factured by Sandoz Pharmaceuticals Corp.).
65Folkenberg supra note 40.
66Novartis supra note 1 at 3. The product literature recommends that even patients who respond beneﬁcially to clozapine
should receive periodic re-evaluations of their need for continuing treatment due to the risks of side-eﬀects.
67Novartis supra note 1 at 4.
14ing the medications. In 1983 Sandoz (n/k/a “Novartis AG”) applied for FDA approval to market Clozaril
for treatment-resistant schizophrenia. However, the FDA’s conservative stance toward drug approvals led
to the denial of Sandoz’s request, due in large part to the danger of agranulocytosis in patients taking the
drug. An FDA advisory committee composed of independent outside consultants, however, encouraged the
company to pursue proof of the drug’s eﬀectiveness in treating schizophrenics whose symptoms were not
reduced by then approved drugs. Thus, the FDA and Sandoz formulated a large research study to test the
drug’s eﬀectiveness.68
The FDA approved Clozaril in 1989 and subsequently approved a new formulation of Clozaril in 1997.69
“The severity and hopelessness of unremitting chronic schizophrenia was an important factor in the decision
to approve Clozaril, despite the fact that it is associated with some serious risks,” said Paul Leber, M.D.,
FDA’s director of the division of neuropharmacological drug products. Although the FDA noted that there
was no objective way of measuring the risk versus the beneﬁts of approving the drug, the FDA considered
approval of the drug a risk worth taking.70 Patient advocate groups likewise considered the risks associated
with the drug insubstantial considering the beneﬁts the drug might contribute to patients in need. “We
think that the potential risk for death is worth the beneﬁt Clozaril brings for people who have almost no
life of their own,” stated a representative of the National Alliance for the Mentally Ill, an organization made
up of patients and the relatives of the severely mentally ill.71 Though the FDA and patient advocates had
stated that the use of clozapine represented a risk they were willing to take due to the enormous potential
beneﬁts that the drug could provide for schizophrenics, laws and policies by government, drug manufacturers
and health care providers alike established signiﬁcant obstacles to access to the medication that were severe
enough to prohibit many from beneﬁting from treatment with clozapine.
68Folkenberg supra note 40.
69Patlak supra note 3.
70Folkenberg supra note 40.
71Id.
15The lack of access to treatment during initial marketing and distribution of clozapine, though it had gained
FDA approval, was a harbinger of problems to come regarding access to the atypical antipsychotics. FDA
approval of the drug did not lead to easy access to the medication by the public. Due to the risk of agranulo-
cytosis and the accompanying threat of product liability to the manufacturer, Sandoz instituted a bundling
policy in which it would sell clozapine only as part of a package that included blood monitoring. This sys-
tem was called the “Clozaril Patient Management System” (“CPMS”).72 Sandoz had arranged for the blood
monitoring to be performed by one of two for-proﬁt companies, which it had under contract.73 Although the
FDA had required a monitoring program as a condition to approve the drug, the requirement did not specify
that Sandoz itself or one of its aﬃliates was to perform the monitoring.74 On the contrary, in 1990 the FDA
wrote to the company in order to protest the labeling of the drug, which appeared to require monitoring by
Sandoz (or Sandoz-speciﬁed aﬃliates) alone.75
Sandoz claimed that the bundling requirement did not represent a mere marketing ploy by the company
as suggested by some opponents of the bundling policy, but that the cost of the drug and the associated
monitoring requirement ensured the utilization of the best possible monitoring system by patients using its
drug. Gilbert Honigfeld, Sandoz’s business director stated, “We want to give people access, but access in
the safest possible manner. We don’t want to get in trouble here. And getting into trouble with a new drug
basically means people die and the drug is pulled oﬀ the market.”76
When introduced to the market, clozapine became one of the most expensive medications in the United
States. Sandoz charged approximately $172 per week or $9,000 per year per patient for its “bundled” pack-
age of medication and monitoring.77 By comparison, the price of the medication in Europe was far lower,
72Swidler supra note 41 at 668.
73Id.
74Spolar supra note 49.
75Id.
76Id.
77Swidler, supra note 41 at 668.
16reportedly $20 to $40 per week per patient!78 Sandoz explained that the discrepancy in pricing stemmed from
the greater exposure the company had to product liability litigation in the United States.79 This “bundling”
arrangement ceased in May of 1991, when Sandoz dropped the bundling requirement due to increasing pres-
sure from Congress, the states,80 and patient advocacy groups, who claimed that the tying arrangement
constituted antitrust violations and price- ﬁxing on a drug over which Sandoz held a monopoly.81 The
manufacturer agreed to sell clozapine to purchasers who could ensure proper blood monitoring.82
The removal of the bundling requirement had immediate eﬀects on patient access to the medication. In
response to the reduced cost, which had fallen to $5,400 per year per patient without the tying arrangement,
New York announced that it would make clozapine available under its Medicaid program. Two weeks after
this announcement, the United States Department of Health and Human Services ordered all State Medicaid
programs to pay for clozapine, agreeing in turn to pay for half of the drug and monitoring costs.83
Currently, distribution of the drug continues to require that strict monitoring procedures be met. Before
initiation of treatment with clozapine, patients must submit a blood sample for a white blood cell count, and
must submit thereafter to weekly tests of their white blood cell counts for the ﬁrst six months of continuous
treatment.84 Provided white blood cell counts remain acceptable, the monitoring may slow to every other
week. In addition, after cessation of treatment with clozapine, the patient must submit to further blood
tests for an additional four weeks.85
78Id.
79Id.
80Sandoz settled the antitrust action, agreeing to pay approximately $20 million to the twenty-nine Plaintiﬀ states. See
Sandoz Settles with States on Clozaril Antitrust Lawsuit, Wash. Post. Sept. 4, 1992, at F3.
81Swidler supra note 41at 670; see also In re Clozapine Antitrust Litig., Multdist. Litig. No. 874 (N.D. Ill. 1990); see Ron
Winslow, Sandoz Unit Faces States’ Antitrust Suit Over Marketing of Schizophrenia Drug, Wall St. J. Dec. 19, 1990, at
B8. See also Consent Order, FTC Notice, Dkt. C-3385, August 13, 1992 (explaining that consent order issued July 28, 1992
prohibited the company from requiring any purchaser of the drug or patient taking the drug to buy other goods or services
from Sandoz or anyone designated by Sandoz. The consent order also required that Sandoz provide a reasonable response to
any company’s request for information about patients who have had adverse reactions to clozapine).
82Swidler supra note 41 at 670.
83Swidler supra note 41 at 671; see also Milt Freudenheim, Medicaid Payment Ordered for Drug for Schizophrenia, N.Y.
Times, May 25, 1991, at A1.
84Novartis supra note 1at 5.
85Id.
17Any policy or reform established regarding atypical antipsychotic treatments must require vigilant monitor-
ing. The lack of strict monitoring may, indeed, pose a risk to patients. Dr. Fritz Henn, chairman of the
psychiatry department at the State University of New York at Stony Brook, L.I., expressed such a concern.
“Many of our patients are in state institutions where the levels of care are variable.”86 Thus, it is clear that
some careful balance must be reached between access and ensuring safe use of the drug.
IV. Newer Atypical Antipsychotics: Olanzapine and Risperidone
The acceptance of the use of clozapine by clinicians treating schizophrenic patients cleared a path for the
development of newer generations of atypical antipsychotics, most notably, olanzapine and risperidone. Al-
though much research exists conﬁrming the general superiority of the atypical antipsychotics as a class over
their conventional or traditional counterparts, scarce research exists regarding one atypical’s superiority over
another.87
Olanzapine and risperidone claim the same beneﬁts as clozapine, including the treatment of negative as
well as positive symptoms of schizophrenia, while avoiding the problems with extrapyramidal symptoms and
tardive dyskinesia experienced with traditional antipsychotic medications. Risperidone and olanzapine oﬀer
the additional and important beneﬁt of avoiding the potentially fatal condition of agranulocytosis, which
poses a high risk to those who undergo treatment with clozapine.
86New Drug is Said to Help Severe Schizophrenics, N.Y. Times, May 15, 1987, at B12.
87In a summary of clinical studies comparing the relative eﬃcacy of clozapine, risperidone and olanzapine, one author stated:
“A total of 10 head-to head trials have been conducted comparing various atypical antipsychotics. In these investigations,
risperidone has been the most examined and has been included in nine of the 10 trials. Clozapine and olanzapine have also
been included in such studies. One point to consider is the diﬀerent methods used in each of these examinations. They have
diﬀered on binding, sample size, patient population, dosing schedules, mean doses, and, of course, outcomes. As clinicians, it
is hard to determine which results can be generalized to clinical practice. Most appropriate dosing of these medications is still
being investigated; this fact should be taken into account when evaluating head-to-head trials. All of the trials presented have
involved relatively small sample sizes.” Donald Rogers, Pharm.D, Comparing Atypical Antipsychotics, 19 Psychiatric Times
1 (2002).
18Johnson & Johnson introduced its atypical antipsychotic, risperidone, in 1994 under the brand name of
“Risperdal.” Those who had an interest in the treatment of schizophrenia welcomed the introduction of
the drug due to its detachment from the risks of agranulocytosis and seizure that plagued its predecessor,
clozapine.88 Risperidone, like clozapine, in active comparator studies, proved itself equal or superior to
conventional neuroleptic agents in terms of both positive and negative symptom relief.89 Furthermore,
some studies suggest that risperidone outperforms clozapine in treating patients with severe delusions and
hallucinations.90 However, extrapyramidal symptoms frequently emerge with higher dosages of risperidone,
though the development of tardive dyskinesia did not evidence itself in trials.91
Olanzapine was introduced on October 1, 1996, when the FDA approved the new atypical antipsychotic
manufactured by Eli Lilly & Co. under the brand name of “Zyprexa.” Some commentators believe that
olanzapine provides many of the beneﬁts of clozapine without some of its more severe negative side-eﬀects.92
In addition, studies of olanzapine show that the drug has long-term eﬃcacy. Furthermore, the FDA made
olanzapine the ﬁrst drug to receive its approval for the maintenance therapy of schizophrenia.93 Olanzapine
may stand out as the superior atypical antipsychotic due to its eﬀectiveness in treating positive and negative
symptoms without the side-eﬀects posed by both clozapine and risperidone.
88Ramsey & Ross supra note 32.
89Id.
90Rogers supra note 87.
91Ramsey & Ross supra note 32.
92See infra note 94.
93Ramsey & Ross supra note 32.
19“Multinational clinical trials comparing olanzapine with conventional neuroleptic agents and placebo
have found evidence for improved eﬃcacy in psychosis. One trial, evaluating 1996 patients in 17
countries, showed that olanzapine (5-20 mg per day) was signiﬁcantly better than haloperidol (5-
20 mg per day) in reducing psychotic symptoms. The beneﬁt was especially striking for negative
symptoms, and subsequent analyses have indicated that the eﬀect is directly related to the drug’s
action on the core deﬁcits of schizophrenia, rather than being secondary to lesser induction of
extrapyramidal symptoms or due to an overall superior antipsychotic action. Schizophrenic patients
who had comorbid depression also showed more of an antidepressant response to olanzapine than
to haloperidol, and in the group overall, changes in quality-of-life indicators favoured olanzapine.
Olanzapine patients had fewer extrapyramidal side-eﬀects, a lower dropout rate over the course of
the study, and a lesser incidence of tardive dyskinesia over the course of a year. The only frequent
(greater than 10%) undesirable side-eﬀects observed were weight gain and drowsiness...”94
On the other hand, risperidone may prove to be an attractive alternative to both clozapine and olanzapine due
to its more aﬀordable price. A Risperidone Olanzapine Drug Outcomes Study in Schizophrenia (“RODOS”)
conducted by the Janssen Research Foundation95 determined that risperidone reduced the cost of treating
schizophrenics on several diﬀerent levels. First of all, the use of the drug as compared to the use of olanzapine
resulted in a savings of $2.80 per patient per day, or $1,022 per patient per year, making the cost of olanzapine
50 percent higher than that of risperidone. According to the RODOS study, the results were consistent across
the 61 centers, and nine countries included in its study. Furthermore, all inpatient drug use was signiﬁcantly
higher in the olanzapine group than in the risperidone group. And lastly, the RODOS study showed that
risperidone-treated patients were discharged sooner than olanzapine-treated patients, resulting in savings
due to shortened hospital stays.96 The cost-eﬀectiveness of risperidone may prove invaluable in providing
schizophrenics with treatment in a managed care health care system with extremely regulated and limited
resources. Physicians, in making treatment decisions must, of course be mindful of eﬃcacy as well as cost
concerns.
95Janssen Research Foundation is a Johnson & Johnson - aﬃliated organization.
http://www.janssenpharmaceutica.be/about/index.stm.
96Schizophrenia: newer antipsychotic medicine saves money, Pain & Central Nervous System Week, July 29, 2000,
21-22.
20The atypical antipsychotics, generally, have their own share of drawbacks and limitations, which have im-
pacted compliance rates in patients. For example, concerns about weight gain and the consequent de-
velopment of metabolic abnormalities have caused some patients to discontinue taking their medication.97
However, given that the resultant weight gain seems to be one of the most consistent side-eﬀects of the atyp-
ical antipsychotics, it certainly seems worthy to support them as ﬁrst-line treatments over the conventional
antipsychotics, which cause far more severe and potentially irreversible and/or fatal adverse eﬀects.98
Furthermore, use of a conventional antipsychotic for ﬁrst-line treatment may have greater and more severe
consequences than the waste of resources alone. Delay of eﬀective treatment reduces the likelihood that
the patient will have a good response to therapy.99 Indeed, studies have shown that when a schizophrenic
receives treatment after a relapse, (which is a far greater possibility when undergoing treatment with the
conventional antipsychotics) therapeutic responses become successively weaker, emphasizing the need to
provide eﬀective treatment as soon as possible and reducing the potential for relapse.100
In addition, risperidone may provide a solution to the signiﬁcant problem of compliance.101 Current research
shows that risperidone may soon be available and marketed in a long-acting, injectable form. This new for-
mulation, called “Risperdal Consta” currently awaits the approval of its new drug application with the FDA
and regulatory agencies worldwide.102 The drug utilizes microsphere technology, which gradually releases
it into the body, allowing the body to maintain stable blood levels for two weeks.103 Currently, the only
97Advisory Committee Transcript supra note 6 at 24.
98Atypical Antipsychotics May Be Used In First-Line Of Brain Disorders, Doctor’s Guide, Global Edition (1997), at
www.pslgroup.com/dg/4a596.htm. (The introduction of atypical antipsychotics as ﬁrst-line medications represents an unrivaled
turning point for the more than ﬁve million Americans suﬀering from the most debilitating brain disorders,said NAMI executive
director Laurie Flynn. The new drugs oﬀer these individuals renewed hope and exciting new possibilities for full and productive
lives. Unfortunately, however, far too many people with chronic mental illnesses are denied access to these life-changing
remedies.).
99Joan Stephenson, PhD, Delay in Treating Schizophrenia May Narrow Therapeutic Window of Opportunity, 282 J. Am.
Med. Ass’n, No. 16 (April 26, 2000) at
http://jama.ama-assn.org/issues/v283n16/ffull/jmn0426-1.html.
100Id.
101Weidan, Shaw & Mann, supra note 24.
102Schizophrenia: New Data Suggest Long-Term Eﬃcacy of Risperidone, Pain & Central Nervous System Week 24 (via
NewsRx.com) (Jan. 21, 2002).
103Id.
21available long-acting antipsychotic drugs are the conventional drugs, accompanied by their sometimes-severe
side-eﬀects.104
The lack of a single, “perfect” treatment for schizophrenia should not discourage physicians, patients, or
policy-makers in ensuring that the drugs are made available to patients. On the contrary, policy-makers
should work to increase availability and access to the medications so that physicians and patients may make
informed decisions as to the best course of treatment for each individual patient. Only this interaction and
exchange by physician and patient, made on a case-by-case basis, may accurately determine which individu-
als would most beneﬁt from each medication. Ideally, reimbursement hurdles, managed care restrictions and
threats of tort liability should not overshadow these determinations of eﬃcacy.
V.
The Biological/Physiological Beneﬁts of Atypical Antipsychotics – Treating a
Physical Illness
“[S]chizophrenia is an eminently treatable disease” similar to diabetes in that medications may be used to
treat the symptoms of the disease without necessarily curing the individual of the disorder.105 “[E]vidence
is now overwhelming that brains of persons who have schizophrenia are, as a group diﬀerent from brains of
persons who do not have this disease.”106 Thus, it seems clear that the current divide between coverage for
physical and mental illness, even when the mental illness has a biological basis, exists because of prejudice
and stigmatization of the mentally ill.
This stigma results in part from ignorance or a lack of understanding of the nature of severe mental illnesses,
104Id.
105Brian D. Shannon, The Brain Gets Sick, Too – The Case for Equal Insurance Coverage for Serious Mental Illness, 24 St.
Mary’s L.J. 365, 369-70 (1993).
106Id. at 369.
22and also in part from a refusal to believe that the symptoms exhibited by the mentally ill could possibly
have a physical basis. “Many members of the public and the insurance industry still view individuals with
mental illness as causing their own mental problems. Consequently, this segment of the public believes that
persons with mental illness should be able to overcome their illness simply by their own eﬀorts.”107 However,
current scientiﬁc evidence should not be dismissed. Moreover, societal ignorance or prejudice should not be
supported or tolerated by government regulation (or lack thereof). The maintenance of the disparate treat-
ment given to mental health care as compared to “physiological” health care only perpetuates discriminatory
attitudes toward the mentally ill, and should be reformed to address this problematic result.
Should the argument that schizophrenia represents a biological physical illness of the brain prove uncon-
vincing, one may also consider that treatment with atypicals have independently physiologically beneﬁcial
eﬀects. The use of atypical antipsychotic medication, including risperidone and olanzapine, also have wider-
reaching beneﬁts on physiological health as indicated by Tony George, M.D., assistant professor of psychiatry
at Yale School of medicine and lead author of a study on smoking and drug use by schizophrenic patients:
“[N]ewer medications used to treat schizophrenia also might be helpful for these patients in treating smoking
and other types of drug dependencies...And because so many schizophrenics smoke,108 this ﬁnding could
have substantial public health implications.”109 Although smoking may seem a relatively minor and tan-
gential problem to the problem of treating the disorder itself, the shockingly high rates of smoking among
schizophrenics should be addressed if possible. Seventy to 90 percent of patients with schizophrenia smoke
cigarettes, as compared to 25 percent of smokers in the general population.110 “Rates of certain diseases,
particularly cardiovascular disease, are much higher among schizophrenics.” 111
107Id. at 371.
108An estimated 90 percent of schizophrenics smoke. Advisory Committee Transcript supra note 6 at 25.
109M2 Presswire, New Antipsychotic Drugs Combined with Nicotine Patch Help Schizophrenics Quit Smoking, November
16, 2000, (available on Westlaw).
110Advisory Committee Transcript supra note 6 at 25.
111M2 Presswire supra note 109.
23The atypical antipsychotics are particularly eﬀective in curbing smoking by schizophrenics due to the fact
that many patients smoke to lessen the movement disorder symptoms that schizophrenics experience when
taking traditional antipsychotics such as Haldol and Thorazine.112 In addition to quit rates alone, the study
investigating this theory objectively measured smoking by monitoring carbon monoxide levels, which are a
by-product of cigarette smoke. The levels of carbon monoxide were substantially less in patients prescribed
the atypical antipsychotics.113
As our country enters a period of advanced scientiﬁc research and developments, in which access to infor-
mation regarding the biological and physiological nature of severe mental illnesses such as schizophrenia
becomes increasingly available, health care reforms should cast aside outdated beliefs regarding the nature
of mental illness. Severe mental illnesses, such as schizophrenia in particular, that have clear physiological
causes as well as physical or biological consequences should receive health care coverage comparable to that
enjoyed by individuals who suﬀer from other physiological disorders or illnesses.
VI. State of Mental Health Care in United States
The second-class citizenship status of mental health patients in relation to patients seeking treatment for
physiological illnesses has been under attack in the United States in recent years. Increased awareness of
the impact of mental health on an individual’s well-being continues to shape American health care policy,
as well as the attitude of Americans in general toward the mentally ill and their care.
Schizophrenia has been referred to as a “barometer of mental health care policy in this country for decades.”114
Thus, by examining the diﬃculties faced by schizophrenics in receiving medical coverage, we can achieve some
sense of how mental health care policy is developing and treated overall. Due to the misunderstood nature
of schizophrenia and the stigma associated with the disorder, reforms on schizophrenia have unfortunately
112These drugs cause muscle stiﬀness and abnormal facial and extremity movement because they block the subclass of dopamine
D2 receptors in regions of the brain that control movement. Risperidone and olanzapine block dopamine receptors in motor
pathways to a lesser extent. See M2 Presswire, supra note 109.
113Id.
114Lehman, supra note 13.
24been driven less by medical knowledge and more by misguided, though “prevailing social attitudes and be-
liefs.”115 The Surgeon General’s Report on Mental Health, issued in 1999, stated that mental and behavioral
disorders aﬀect approximately one in ﬁve Americans every year.116 The report discussed the importance of
mental health care, stating, “Appreciation of the clinically and economically devastating nature of mental
disorders is part of a quiet scientiﬁc revolution that not only has documented the extent of the problem, but
in recent years has generated many real solutions” and further, that the “artiﬁcial centuries-old separation
of mind and body” should cease.117 However, “mental health is often an afterthought, and illnesses of the
mind remain shrouded in fear and misunderstanding.”118
Historically, mental health services have not received equivalent attention or support as that which is given
to health services for those conditions thought to be distinctly physiological. Both private and public funding
permit “carve-outs” for mental health coverage, which limit beneﬁts for mental health services relative to
physical health beneﬁts.119 Private insurance coverage customarily restricts mental health beneﬁts to a
greater extent, by setting caps on hospital days or outpatient visits, or by imposing spending caps for mental
health services.120 Furthermore, health maintenance organizations (HMOs) customarily establish lifetime or
annual spending caps that limit coverage of diseases such as schizophrenia due to the presumed high cost of
treatment.121
115Id.
116US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center
for Mental Health Services, National Institute of Health, National Institute of Mental Health, Mental Health: A Report of the
Surgeon General – Executive Summary (1999).
117Report of Surgeon General (1999).
118Tammy Chernin, Maintaining Mental Health: The new focus is on maximizing beneﬁts and minimizing side-eﬀects,145
Drug Topics No. 11, 33 (2001).




25B. Reform of Mental Health care Policy
I. Managed Care
The prospect of health care reform in large part requires a resetting of priorities, which is no simple task.
Due to rise of the dominance of managed care and an accompanying concern and obsession with costs and
allocation of resources within an assumed zero-sum framework, a debate on priorities often takes the form of
a choice between alternative treatments or competing populations. Schizophrenic patients may, for example,
be forced to compete for mental health resources in order to purchase needed medication such as clozap-
ine, with populations of those who suﬀer from mild forms and merely episodic forms of mental illness.122
Considering the costly nature of treatments for schizophrenia (at least in the short-term) prejudice against
schizophrenic patients may take the form of preference for treating these milder and non-chronic mental
disorders.
“Proponents of managed care argue that it promotes a fundamental moral goal; namely, conserving scarce
health-care resources by insuring their eﬃcient distribution. Opponents of managed care criticize the ef-
ﬁciency principle because, in an eﬀort to balance individual needs against welfarist concerns of society, it
undermines the fundamental moral commitment of medical practice – advocacy for the individual patient.”123
Indeed, one author suggests that managed care organizations and insurers often obtain “eﬃciency” by tar-
geting mental health care as an ineﬃcient expense; “by selectively marketing to healthier patient groups, or
oﬀering plans that exclude certain treatments, they are able to select enrollees who are likely to use fewer and
cheaper services.”124 Thus, one may easily understand the dilemma schizophrenic patients ﬁnd themselves
in, with regard to receiving coverage for their treatments. Mental health care as a whole remains a target
122Id at 6.
123Stephen A. Green, The Ethics of Managed Mental Health Care, in Psychiatric Ethics 403, (Sidney Bloch, Paul Chodoﬀ,
Stephen A. Green ed., 1999) (emphasis added).
124Id. at 413.
26of managed care for cost-cutting. Within this framework, the most costly treatments, which include the
atypicals, are continually excluded from coverage or are the target of spending caps of health care plans.
II. State Coverage issues
Almost every state125 has adopted managed care in providing some or all of its health care services through
the contracting out of their Medicaid services to private HMOs or managed care organizations.126 Managed
care of conditions relating to mental illness or substance abuse have been termed, “managed behavioral
health care.”127 While some states have separate managed care plans for mental health services than they
have for other health services, other states have plans that include mental health services in their general
plans, but provide an enhanced beneﬁts package for adults with serious mental illnesses, children in or at risk
of state custody and children with serious emotional disturbances.128 “Although highly controversial in the
provider community and of great concern to advocates for the mentally ill, the management of behavioral
health care services is unlikely to go away, because it is a creature of the drive for cost containment aﬀecting
the entire health care system.”129 Thus, health care reform with the goal of providing schizophrenic patients
better access to treatment must operate under the assumption that managed care of mental health care is
here to stay.
125Miles F. Shore, M.D. & Allan Beigel, M.D., The Challenges Posed by Managed Behavioral Health Care, 334 New England
J. of Med. No. 2, 116-119, (1996) (Stating that employers in the private sector have also turned to managed care organizations
that provide managed behavioral health care in an eﬀort to reduce the expense of health care, while increasing “the accountability
of the system in terms of both quality and value.”).
126Susan Stefan, Unequal Rights: Discrimination against people with mental disabilities and the Americans with
disabilities Act 204 (2001).
127Miles F. Shore, M.D. & Allan Beigel, M.D., “The Challenges Posed by Managed Behavioral Health Care,” The New England
Journal of Medicine, Vol. 334:116-119, January 11, 1996, no. 2. p. 116?
128Stefan, supra note 126 at 204.
129Shore & Beigel, supra note 125 at 116.
27Formularies are one of the most common cost-containment devices utilized by managed care organizations.130
Due to the expense of the atypical antipsychotics they are not surprisingly targeted for exclusion in health
care providers’ formularies. Eﬃciency stands as one of the main principles upheld by managed care, leading
to a certain “economism,” which favors provision of beneﬁts for the treatments and illnesses that demand
the least amount of resources.131 This bias for “less expensive” illnesses places the treatments for chronic
mental disorders such as schizophrenia at serious risk of exclusion from formularies.
“Formularies, speciﬁcally, may compromise patient care in several ways. Necessary pharmaceuticals
may be omitted in the process of formulary compilation, either because consolidation results in
pharmaceutical manufacturers favoring their own drugs over the drugs of competitors or because
formulary decisions may fail to account suﬃciently for variations among individual patients. Some
drugs may not provide more beneﬁt than their counterparts on average, but may make a substantial
diﬀerence to a minority of patients. Eliminating the option of what may be better for some inevitably
compromises the care of a small population of patients. In addition, these compromises may not
even be oﬀset by cost savings; increased expenses for a patient who was inadequately treated initially
may far outweigh the savings on the drugs with which the patient was treated.”132
As suggested by this argument, short-sighted eﬀorts to reduce the cost of behavioral health care by struc-
turing formularies to exclude full coverage of atypical antipsychotics as ﬁrst-line treatments, may, in fact,
result in a greater ultimate health care expense. Physicians unable to exercise their own judgment regarding
whether to treat schizophrenic patients with conventional or atypical antipsychotic drugs, and furthermore
unable to freely choose among atypical antipsychotic alternatives, may be forced to knowingly administer
medications that will at best have ineﬀective results and at worst cause severe irreparable harm to the pa-
tient. The obligatory, albeit cheaper, conventional antipsychotic treatment will then represent a mere failed
attempt at treatment and thus, a total waste of time, resources and funding.
Therefore, the patient, if fortunate enough to receive the needed medication, will ultimately undergo treat-
ment with the atypical antipsychotic at further expense, when the treatment could have been administered
130American Medical Association, Council on Ethical and Judicial Aﬀairs, Managed Care Cost containment Involving Pre-
scription Drugs, 53 Food & Drug L.J. 25, 25 (1998). [Hereinafter AMA Council].
131Green, supra note 123 at 403.
28without the previous waste of resources. “Ten studies have proven that unrestricted use of atypical an-
tipsychotics are cost-eﬀective and actually reduce overall health care costs. For example, San Diego County
saved $4,842 per patient per year after patients began taking Risperdal.”133 Furthermore, as discussed later
in this essay, the atypical antipsychotics have additional cost-saving eﬀects, such as a resulting decrease in
hospitalization due to the eﬃcacy of these drugs. “A recent study by the USC School of Pharmacy concludes
that the average cost of treating schizophrenia is $19,000 per patient per year. Unrestricted access to the
newer medications would result in a net savings to the ...budget of $5,000 per patient per year, a 29 percent
savings to the total Medi-Cal budget. That savings more than covers the additional $13 million cost of the
medications to the pharmacy budget.”134
New York and California provide two examples of states that have attempted to revise their mental health
care policies for the speciﬁc purpose of providing greater access to atypical antipsychotic treatments. New
York’s attempt at reform, however, fell somewhat short of successful in the eyes of patient advocates and
physicians, due to the limited nature of physician discretion in prescribing the medications. New York’s Med-
icaid reform attempted to provide access to clozapine without sacriﬁcing concerns about safety, monitoring
or the danger of abuse of the health care system by over-prescription of the drug when unnecessary.
“When New York provided Medicaid coverage for Clozapine in July 1991, it imposed a variety of re-
quirements intended to ensure the safe and cost-eﬀective use of the medication...Most signiﬁcantly,
the State required prior approval by the Department of Health, based on clinical eligibility criteria,
before a patient would be covered; it also required periodic reconsideration of the patent’s clinical
eligibility. Providers were further obligated to agree to provide case management services, primarily
to ensure patient compliance with blood monitoring, without any fee enhancement. Only psychi-
atrists or psychiatric hospital physicians were authorized to prescribe the drug. Finally, Medicaid
would only reimburse for the use of Clozapine for active schizophrenia – not for other ‘oﬀ label’
uses.”135
The limitations deﬁned in the New York reforms provide an example of how behavioral health care reform
133Elimination of ‘Two Strikes’ Policy for Schizophrenia Drugs Could Save Medi-Cal Program $17 Million Annually (May
9, 1997), at www.schizophrenia.com.
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29may prove grand in gesture and intent, but only symbolic in practice. The provision stating that reimbursable
uses of the atypicals required prior approval by the FDA, became a problematic administrative hurdle to
many seeking coverage of their antipsychotics treatments.
The FDA identiﬁes “approved uses” for prescription drugs,136 which the drug manufacture lists in its product
literature, but physicians may also prescribe drugs for unapproved uses.137 “The FDA cannot prevent
physicians from prescribing drugs for unapproved uses; however, liability concerns or managed health care
oversight may prevent physicians from doing so.”138 Therefore, despite the fact that an “approved use” of
clozapine requires prior use and failure of other antipsychotic medications, mental health physicians may
prescribe clozapine without the patient actually having tried the conventional antipsychotics, making the use
of atypicals as ﬁrst-line treatments an “unapproved” use. Thus, even if the medical community accepts the
atypical antipsychotics as appropriate ﬁrst-line treatments, schizophrenic patients are met with the problem
of reimbursement.
The New York provision denying reimbursement for “oﬀ label” or “unapproved” uses presents a problem for
mental health physicians and their schizophrenic patients. The reliance on this criterion assumes that the
explicitly approved and marketed uses of the atypical antipsychotics are the only safe uses and therefore,
the only uses that qualify for reimbursement. However, physicians and pharmacists protested New York’s
clozapine access rules.139 “They complained that the decision to prescribe Clozapine, like decisions to
prescribe other drugs, was a clinical judgment in the sole province of the patient and physician.”140 Indeed,
it seems diﬃcult to dispute such a claim or argument. Mental health advocacy groups likewise responded to
the New York plan in a predictable fashion, “express[ing] their outrage and accus[ing] the State of trying to
136Ronald Hansen, FDA Regulation of the Pharmaceutical Industry, in Hazardous to Our Health? FDA Regulation of
Health Care Products 16 (Robert Higgs ed., 1995) (“Approved” uses are speciﬁed by the FDA at the time a new drug is
approved.).
137Blaschke, Nies & Mamelok, Principles of Therapeutics, in Goodman & Gilman’s The Pharmacological Basis of Ther-
apeutics 49, 58 (A. Gilman & L. Goodman, eds., 7th ed. 1985).
138Hansen, supra note 136 at 17.
139Swidler, supra note 41 at 670-71.
140Id.
30block access with red tape, and of discriminating against patients with mental illness by imposing a screening
system not imposed on other Medicaid clients.”141
Due to the ineﬃciencies of government agencies in administering claims, the type of plan established by New
York illustrates two kinds of problems that may occur with such a behavioral health care coverage scheme.
First of all, FDA approval is required in order for a drug label to include certain uses as “approved.”142
Thus, only those uses that have withstood FDA scrutiny and perhaps more importantly, those uses that have
even reached consideration by the FDA, have a chance of surviving the approval process. The inability of the
FDA to respond quickly to every request for a new drug approval has often been cited as an administrative
hurdle perhaps too great to require FDA consideration before every new use may be added to a drug’s label.
Secondly, even if the prescribed use is “approved” the bureaucratic hurdle of receiving Department of Health
approval before administering drugs such as clozapine, would present barriers to access and ineﬃciencies in
reimbursement that may prove prohibitive to treatment using the atypical antipsychotics.
“Prior authorization [under managed care formularies, for example], which requires physicians to secure
permission from a specialist or other designated person before using high-cost drugs, can unduly discourage
optimal drug therapy. Prior authorization requirements also may increase administrative costs.”143 A serious
consequence of the above type of policy, as demonstrated by New York, is that, “physicians registered their
displeasure with the prior approval process by simply failing to prescribe Clozapine to anyone.”144 Other
studies have conﬁrmed that despite clinical ﬁndings that clearly demonstrate the advantages of prescribing
the atypicals, neither they nor the conventional antipsychotics are being utilized optimally.145
Plans similar to New York’s reformed behavioral health care policy appear to extend equitable coverage
141Id.
142Hansen, supra note 36.
143AMA Council, supra note 130 at 30.
144Swidler, supra note 41at 670-71.
145Lamberg, supra note 33 (In a survey performed at two public mental health clinics in Los Angeles, the researchers found “that
38% received poor-quality medication management, according to criteria derived from national treatment recommendations,
and 52% received inadequate psychosocial care, as deﬁned by lack of case management and family management. Most poor
care ...was likely due to factors that can be modiﬁed.”).
31for severe mental disorders such as schizophrenia. However, in practice, as evidenced by the response of
New York’s mental health care physicians, administrative hurdles can create obstacles signiﬁcant enough to
preserve the status quo, where patients lack access to treatment. Indeed, reforms such as those implemented
by New York may prove particularly insidious to the project of achieving parity in health care laws, because,
at least facially, it appears as though the problem of disparate coverage has been remedied.
Yet another serious consequence of using “oﬀ label” or “approved” uses as a bright-line cut-oﬀ for determining
coverage status of patients for atypical antipsychotics is the resulting lack of incentives for drug manufacturers
to conduct the supplementary clinical research necessary in order to gain FDA approval for additional uses.
Once the drug has been marketed and its initial uses are approved, the additional expense may not be worth
the pharmaceutical company’s time or resources.
Therefore, those who are most able to pay may beneﬁt from the medication’s oﬀ-label uses (because physi-
cians may still prescribe the drugs legally though the uses are not approved), but those who lack adequate
medical coverage or who are unable to pay will remain untreated. This dynamic leads to disturbing distribu-
tive consequences, where the wealthy receive treatment for a life-threatening disease that severely impacts
the quality of life of those it aﬄicts, while the less wealthy may receive inferior treatment at the least and
no treatment at all in the worst case scenario.
One of the FDA’s chief concerns in requiring clinical testing and formal FDA approval in order to label a
treatment as an “approved use” stems from a concern that pharmaceutical companies may take advantage
of the absence of such a rule and market drugs for uses that may prove dangerous to consumers. Consider-
able concern existed about unapproved uses of pharmaceuticals and pharmaceutical companies’ marketing
32of drugs based on unapproved uses.146 Pharmaceuticals may often have uses other than those speciﬁcally
approved by the FDA. Even if the manufacturer is aware of the potential uses during the clinical stages,
such uses may not become approved due to the manufacturer’s decision not to invest further resources to
investigate the additional use or due to the FDA’s refusal to designate the claimed use as approved.147 In
the event that additional uses for drugs are discovered after their approval, a pharmaceutical may conduct
additional clinical trials and ﬁle a supplemental NDA to broaden the claimed uses.148
The FDA has expressed concern about pharmaceutical companies sponsoring or publishing articles in jour-
nals or other medical sources that list uses other than those speciﬁcally approved by the FDA for their
medications.149 The concern stems from the potential for pharmaceutical companies to abuse the current
system that allows physicians to prescribe drugs for unapproved uses, by disseminating information within
medical communities to make the unapproved uses known, and thus to have their drugs used for those
purposes, but to avoid ﬁling supplemental NDA’s, thus avoiding the expenditure of additional resources for
further clinical testing.150 However, given the fact that both the FDA and patient advocate groups have
previously determined that the atypicals, though potentially dangerous, are “a risk worth taking,” restraints
such as this one, permitting only reimbursement of approved uses should be avoided. Only by aﬀording
coverage of atypicals as ﬁrst-line uses (which are currently not approved for clozapine, for example) may
patients receive optimal treatment.
Though New York’s eﬀorts in providing coverage for atypical anti-psychotic treatments began in a positive
direction for schizophrenic patients, clearly, the needs of the schizophrenic community and of their treating
physicians were not met by the limited coverage and stringent requirements of the plan.





33Some years later, in 1997, California followed in the footsteps of New York in providing reimbursement for
atypical antipsychotics, and went even further in providing access to treatment by lifting restrictions similar
to those included in the New York plan. The Department of Health Services for California lifted its former
Medi-Cal restriction, which required prior authorization for reimbursement, by adding all three atypical
antipsychotics medications to the list of drugs available to Medi-Cal recipients.151
More and more states are becoming increasingly aware of the importance of mental health care and are
responding to this new information by enacting their own parity laws.152 However, optimism about a
transformation of health care coverage through state action alone should be tempered by other considerations.
“[W]ith a slowing economy, right-minded state lawmakers and behavioral health agencies suddenly ﬁnd
themselves facing tough choices when it comes to coverage of new generation schizophrenia drugs for special
populations.”153
III. Incentives
Publicly funded managed care presents both a barrier and an opportunity for schizophrenic patients. The
obstacles appear mainly due to managed care’s cost containment-centered policies. Importantly, managed
care presents an opportunity for more eﬃcient and better care for mental health patients by opening a path-
1515 No. 20 Cal. Health L. Monitor 7 (1997).
152United States General Accounting Oﬃce, Mental Health Parity Act: Despite New Federal Standards, Mental Health
Beneﬁts Remain Limited, GAO/HEHS-00-95 (2000) (indicating that twenty-nine states have enacted mental health
parity laws including greater coverage than that required in the Mental Health Parity Act of 1996), available at
http://www.access.gpo.gov/su docs/aces/aces160.shtml.
153Shrinking State Purse Squeezes N.C. Schizophrenia Drug Fund, Behavioral Health Business News, (Jul. 12, 2001), at
http://www.psybermetrics.com/resources/20010712-nc.asp.
34way for integration of primary and mental health specialty care.154 Such coordination would not only ensure
that schizophrenic patients receive proper medical care and monitoring, but would also provide an opportu-
nity for early detection and intervention.155 Currently, managed care policies typically contain “carve-outs”
for mental health care. While these carve-outs may help protect resources set aside for mental health care,
a more eﬃcient alternative, both cost-wise and care-wise, may be to stipulate in managed care contracts a
coordination between behaviorial health care providers and managed care providers, particularly for patients
with severe mental illness.156
One of the primary complaints against managed care relates to physician discretion over patient care. The
criticism is that health care administrators, rather than physicians, are increasingly inﬂuencing pharma-
ceutical utilization decisions.157 Brieﬂy stated, the shift in control has occurred due to the decisions made
by HMOs or other health care plans to restrict their drug reimbursement formularies to “encourage” the
utilization of less expensive or generic drugs.158 Furthermore, drug manufacturers are faced with the choice
of either oﬀering HMOs signiﬁcant discounts on drugs, or otherwise face the exclusion of their drugs from
the plans’ formularies. The shift in control to health care administrators has the troubling result of focusing
on cost, rather than eﬀectiveness of the medications in making treatment decisions.159
The pressure felt by drug manufacturers to either lower their costs or face potential failure in the marketing
of their medications due to lack of prescription by physicians has consequences outside of those impacting
the pharmaceutical companies alone. Such pressures result in a disincentive for drug manufacturers to de-
velop still other eﬀective medications and in any event negatively inﬂuences the research and development
154Lehman, supra note 13.
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35investment incentives of pharmaceutical ﬁrms.160
The FDA’s regulatory involvement also aﬀects research and development incentives of pharmaceutical com-
panies. The FDA requires approval of new drugs prior to their marketing.161 “The FDA’s inﬂuence extends
to the research and development process leading up to market approval as well as to the manufacturing
of the product and the marketing claims that the ﬁrm can make.”162 Therefore, the FDA’s decisions on
drug approvals aﬀect the costs of developing drugs and the availability of new innovations in treatment, as
well as inﬂuencing incentives by drug companies to further their research and development.163 This positive
reinforcement of drug research was evidenced by FDA approval of clozapine in the 1970s, which has led to
the development of new generations of atypical antipsychotics such as risperidone and olanzapine. These
new generations of atypical antipsychotics oﬀer the potential for increased eﬃcacy, better patient compli-
ance with treatment, decreased chance of severe side-eﬀects, reduced relapse potential, and importantly, are
oﬀered at a far lesser expense.
IV. Private Providers
The majority of Americans who have private health care coverage receive such coverage through their em-
ployers.164 Although most of these employer-provided plans include some mental health care coverage, most
severely restrict the extent of coverage for mental health care by placing caps on hospital stays or outpatient
visits, and by requiring a higher percentage co-pay for those seeking treatment of mental disorders.165 With
chronic mental disorders such as schizophrenia, one can imagine that these limited resources are rapidly
depleted, leaving patients with no recourse for funding of treatments such as the atypicals that are critical
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36would provide relief to the large population of Americans who require additional reimbursement in order to
treat their mental conditions.
Though more and more states are joining the eﬀort to oﬀer parity in insurance coverage to mentally ill
citizens, federal action must supplement the state eﬀorts in order to achieve a comprehensive scheme of
parity legislation.
“Although these state mandates reach a number of persons with mental illness, they do not go far
enough because of existing federal law. State legislatures have the authority to mandate coverage
levels for mental illness (or other ailments) as part of their power to regulate insurance. Indeed,
the Supreme Court has upheld the states’ right to impose mandates for mental illness coverage on
insurers. On the other hand, the Court has also determined that the Employee Retirement Income
Security Act (“ERISA”) preempts the ability of the states to impose similar mandates on fully self-
insured employee beneﬁt plans. In turn, lower courts have determined that fully self-insured health
care plans do not constitute insurance and, accordingly, are not subject to state regulation. Thus,
state statutory mandates cannot direct coverage for many employed citizens because their employers
have decided to self-insure.”166
Despite the need for federal legislation for parity, federal eﬀorts at mandating mental health parity through
enactments such as the Mental Health Parity Act of 1996, remain ineﬀective in practice due to the ﬂexibility
oﬀered to private employers in formulating their insurance policies (discussed below).
C. Considerations for Reforming Policy
I. A Non-Discrimination Standard
Health care reform meant to address mental health issues can take on several diﬀerent approaches. At a
minimum, one approach could require non-discrimination against the mentally ill. However, optimally bene-
ﬁcial health care reform for the mentally ill would provide parity in the form of either equal funding or equal
treatment on the same conditions and terms as physical health services.167
167Boyle & Callahan, supra note 114 at 5.
37The inequitable treatment of the mentally ill with regard to health care coverage represents a mere piece
of a larger story of discrimination experienced by the community. Mentally ill patients face potential dis-
crimination in many facets of their lives. They may be excluded or overlooked in employment, education,
health care, insurance, misrepresented or degraded by media or experience damaged or discriminatory family,
romantic, or other personal relationships.168 In limited ways, the mentally ill may use the legal system to
battle such discrimination. Of particular relevance to this discussion is the ability of schizophrenics to use
the legal system in order to obtain parity in insurance coverage of mental disabilities on the level of the
coverage oﬀered to patients with physical disabilities. Signiﬁcantly, discrimination against those with mental
handicaps is not represented by single, discrete events that are easily addressed through legal action. “It is
not only that people are rejected by their family and shunned by their friends; dismissed from school; scruti-
nized uneasily or ﬁred at work; patronized by doctors and refused coverage by insurance companies; denied
with institutionalization, but also that all of these things happen in interrelated and long-term ways.”169
II. Who should decide?
The democratic process may not be the best or fairest means of determining priorities when it comes to
reallocating resources or reprioritizing health care considerations. Alternatives exist, such as the use of
experts or deference to public oﬃcials.170 However, in order to protect the legitimacy of our democratic
system and to protect public oﬃcials willing to make hard decisions, one consequence may be that such
decisions must be made behind closed doors. Furthermore, some advocates of keeping this decision-making
progress more out of the public’s view propose that “patterns of invidious bias against persons with mental
illness are so rampant throughout society that the decisions must be made by knowledgeable and sympathetic
168Stefan, supra note 126 at 4.
169Id.
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38specialists or oﬃcials.”171
A proposal advocating that oﬃcials not listen blindly to majority rule is not one so foreign to the Ameri-
can way of policy-making. For example, the Civil Rights Movement and in particular Title VII have been
discussed using similar language – the need for government oﬃcials to set policy in the face of a hostile or
unwilling majority for the establishment of a policy thought to distribute a just end. In fact, one of Title
VII’s purposes was to change majority opinions about populations that had been historically discriminated
against– the idea being the removing barriers to those minority populations would dispel certain stereotypes
and stigmas attached to being members of those groups, which would thereby lead to a more integrated
and functional community. Perhaps the implementation of a non-discrimination standard in mental health
legislation would likewise dispel myths and stereotypes attached to the mentally ill.
III.
Legislation
In a hearing before the Senate on the possible reauthorization of the Mental Health Parity Act, the ﬁnal
report to Congress by the National Advisory Mental Health Council stated,
The challenge for the coming decade is to develop clear standards based on the best evidence and
clinical judgment so that parity has substance in implementation as well as in concept. Parity is not
simply some match in service limits to what a medical or surgical patient experiences. It should be a
conﬁguration of management strategies ﬁtted to careful assessment of patients’ needs and a response
that is consistent with our best scientiﬁc knowledge.172
Hope exists for schizophrenic individuals seeking resources for treatment. Medicare currently provides the
primary health care coverage for the 5,000,000 non-elderly, disabled people on Social Security Disability
171Id.
39Insurance.173 Beneﬁts provided by Medicare reﬂect an “outdated bias toward institutionally based service
delivery” that discriminates against mentally ill Americans under its coverage.174 Fortunately, Congress
has, consistent with the rising national awareness of the need for resources for behavioral health care, ﬂirted
with legislation to address the interests of the mentally ill. A bill, entitled the “Medicare Mental Health
Modernization Act of 2001”175 proposes to eliminate Medicare’s 190-day lifetime cap on inpatient psychiatric
services.176 The bill further provided for the reduction of the 80 percent co-pay for outpatient mental health
services to a 20 percent co-pay, similar to the share charged for other outpatient care.177 Though the
legislation still awaits passage, if the Act were to become law, Medicare would oﬀer equal coverage for mental
illnesses and physical illnesses. Furthermore, the bill as written seeks to include coverage for community-
based mental health services, which would prove invaluable to the treatment of schizophrenic patients and
would certainly assist in preventing relapse episodes in schizophrenic patients.178
The Medicare Mental Health Modernization Act of 2001 is currently still under consideration, but has
received the resounding support of mentally ill patient advocate groups such as the National Alliance for the
Mentally Ill (“NAMI”).179 The support for parity stems from the frustration by the mentally ill community
with the long history of unequal treatment for mentally ill patients in public and private health care provisions
alike.
NAMI has pointed out that Medicare imposes conditions and limitations that even private insurance plans
would not impose upon treatment for mental illness. Such conditions include “no coverage for outpatient
173Medicare Mental Health Modernization Act, supra note 8 at 4.
174Id.
175Medicare Mental Health Modernization Act, supra note 8.
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179Statement and Letter from NAMI President Jackie Shannon in support of the Medicare Mental Health Modernization Act
of 2001, at http://www.nami.org/update/20010409.html.
40prescription drugs, a 50% co-payment requirement for outpatient services and 190-day lifetime limit on
inpatient days.” These conditions apply only to mental illness to the exclusion of other medical conditions.180
Other criticisms include the suggestion that inequities result from Medicare’s tendency to “too often focus
only on the needs of elderly beneﬁciaries.”181 It is evident that until recently, the needs of the mentally ill
community have been either ignored or misunderstood. However, current attempts at legislation represent
at least an eﬀort by Congress to address inequities in coverage for this neglected community.
Proponents of mental health parity obtained one victory in 1996, when Congress passed “The Mental Health
Parity Act of 1996”.182 The Act represented an intended compromise between supporters of full parity and
opponents who argued that full parity in coverage would bankrupt insurance companies.183 The act requires
that for plan years beginning in January 1, 1998, and ending October 1, 2001, the group health plans for
companies with greater than 50 employees that provide mental health coverage must provide equal lifetime
beneﬁt caps.184 An exception exists for companies that can demonstrate that this requirement would raise
their health insurance costs by one percent or more per year.185
Vocal opposition followed the passage of the act, due to a fear that the legislation would cause an explosion
of health care costs for employers in the private sector, in particular. However, the fears of opponents were
misplaced. The actual realized beneﬁts attributable to the Act have been largely illusory.186 First of all, the
180Id.
181Id.
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183Stefan, supra note 126 at 278.
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41one percent exception mentioned above most likely favors employers who oﬀer the most egregious disparities
in coverage leading to two results. One consequence of the exception is that employers who are the worst
oﬀenders of mental health parity are the very employers that are exempted from compliance with the act!
Another consequence of the exception is that it gives employers an incentive to create a greater disparity in
the coverage of mental versus physical illnesses, so that they may make a showing that compliance with the
parity requirement would raise their health care costs above the one percent cut-oﬀ.
Lobbyists for the mentally ill have responded to the one percent exception with suggested alternatives. These
advocates187 have proposed that requests for exemptions by employers undergo formal review and approval
by the government.188 Anticipating that enforcement or monitoring by the government may prove to be
problematic due to a lack of resources or lack of stringency of review, the lobbyists have further proposed
that advocates for the mentally ill be permitted to inspect cost estimates and data supporting employer
applications for exemption. 189 Predictably, employers have resisted such suggestions, stating that random
audits alone will ensure compliance.190 Congress’s task in formulating eﬀective parity legislation must create
a careful balance between providing parity and respecting employers’ liberty interests in maintaining their
businesses and employees as they judge appropriate.
The policy implications of the Mental Health Parity Act extend still further, but potentially to the detriment
of those meant to beneﬁt from its enactment. The passage of this legislation led to some unexpected
consequences in interpretations of the Americans with Disabilities Act that adversely aﬀected the interests
of the mentally ill. For example, courts have used the legislation as support for holdings that the ADA
does not apply to health insurance, because Congress’s separate legislation explicitly in the area of insurance
187Robert Pear, Parity in Mental Health Beneﬁts May be Diluted by White House, N.Y. Times, October 21, 1997 ( Advocates
include Coalition for Fairness in Mental Illness Coverage, which includes the National Alliance for the Mentally, Ill, the National
Mental Health Association, the American Psychiatric Association, the American Psychological Association and the American




42shows that the two are distinct in coverage.191 Moreover, the parity legislation has similarly been used to
argue that the ADA does not apply to disability beneﬁts, despite the fact that the Mental Health Parity Act
does not itself cover disability beneﬁts.192
It appears that the disadvantages of the Act may outweigh any real beneﬁts gained from its passage, due
to the ability of health plans to maneuver through loopholes in order to escape requirements that may have
any real impact on coverage. For example, because group insurance plans are yet free to limit actual oﬃce
visits and to limit reimbursement paid for each visit, the “equal” lifetime beneﬁt cap set for mental health
services may never in reality be reached.193 Furthermore, under the Mental Health Parity Act of 1996,
health plans may implement or continue to use disparate co-payment charges for mental health and physical
illness, as well as providing disparate coverage for inpatient and outpatient care.194 The Act certainly does
not represent an airtight eﬀort by Congress to provide equal access to medical resources to the mentally ill.
The Medicare Modernization Act of 2001 represents a step further in the direction of accessing true parity,
but the fate of the bill as yet remains uncertain.
As for the ﬁnancial impact on insurance companies, studies show that they may actually be turning a proﬁt
from the increased coverage required by the parity legislation rather than suﬀering from increased costs.
Insurance companies that provide parity in coverage charge between 7.5 percent and 21 percent more than
standard premium costs.195 However, the actual increase in cost for providing full parity does not appear to
justify this level of price increase.196 Still, when considering the impact real full parity would have on policy
191Stefan, supra note 126 at 279; see also Modderno v. King, 82 F.3d 1059 (D.C.C. 1996).
192Stefan, supra note 126 at 279; see also Ford v. Schering-Plough, 145 F.3d 601, 610 (3rd Cir. 1998);
EEOC v. CAN, 96 F.3d 1039, 1044 (7th Cir. 1996); Parker v. Metropolitan Life, 121 F.3d at 1017-1018
(1997); Rogers v. Department of Health and Environmental Control, 174 F.3d 431, 436 (4th Cir. 1999);
Conners v. Maine Medical Center, 42 F.Supp. 2d 34 (D. Me. 1999).




43premiums, the eﬀect would remain relatively small even if the realization of parity resulted in a signiﬁcant
increase in the use of mental health services, due to the fact that mental health treatment expenditures as
a whole represent a relatively small fraction of all health expenditures.197
D. Cost-Eﬀectiveness of Providing Access to Atypical Antipsychotic Treatments
In evaluating the cost-eﬀectiveness of the atypical antipsychotic agents, factors included in the decision-
making process should “focus on changes in symptoms, substance abuse, suicide, aggression, hostility, func-
tional status, access to and use of resources and opportunities, life satisfaction, family well-being, and patient
satisfaction with intervention.”198
An attempt at reformulating or revising current mental health care policy may not, however, ignore the eco-
nomic consequences that such a reform will have on existing resources for health care. The ever-rising cost of
health care continues to push the bounds of both public and private budgets. Opponents of providing greater
health care coverage claim that rising health insurance costs are, for example, disadvantaging American cor-
porations from competing in American markets due to the rising costs of employees’ and retirees’ health
insurance.199 Many international competitors beneﬁt from lower overhead, lower prices and thus greater
competitive advantage aﬀorded by their governments’ funding of health services in those countries.200 “It is
not likely that society can curb the accelerating cost of health services and at the same time oﬀer everyone
every service of any possible beneﬁt. Choices will have to be made about what services are more or less vital
or expendable.”201
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44Behavioral health care reform may reconcile the need for cost-eﬀective drugs and the need for access to
the atypical antipsychotics. Two arguments in particular suggest that providing atypical antipsychotics as
ﬁrst-line treatments may indeed be a cost-eﬀective practice. First of all, the atypical antipsychotics prove
more eﬀective than the conventional antipsychotics, which results in a reduced need for hospitalization and
use of additional medical resources. Secondly, the introduction of newer, more aﬀordable, and less dangerous
atypical antipsychotics such as risperidone and olanzapine may render the debate on the costs of clozapine
under our current health care system less relevant.202
The controversy and reluctance to supply these prescription drugs to patients using public funds or managed
care relies on an underlying assumption – that the net costs of the drugs will be more than that of the
current costs already expended in supporting the large number of schizophrenics who are chronically and
totally disabled due to the lack of eﬀective treatment of the illness. As a matter of fact, studies have shown
that treatment with atypical antipsychotics such as clozapine for treatment-resistant populations203 actually
decreases the cost of treatment of schizophrenics signiﬁcantly primarily due to a dramatic decrease in the
frequency and cost of rehospitalization.204 One quote estimates that keeping patients out of the hospital a
mere ﬁve to ten days a year will “easily [ ] cover the roughly $2000 cost of an entire year’s medication.”205
In addition, the greater tolerability of the atypical antipsychotics may result in greater patient compliance
with drug therapy, thus reducing the amount of rehospitalization. “Even though the newer agents are consid-
erably more expensive, their downstream cost beneﬁts justify more widespread use...For example, in large
state or V.A. hospitals, it might be possible to close one psychiatric unit or ward as the inpatient population
202Though, keep in mind that the newer antipsychotics may not be as eﬀective as clozapine. As shown in notes 87-96,
risperidone and olanzapine do appear to exhibit substantially similar beneﬁts as clozapine, as well as some further beneﬁts such
as avoiding severe side-eﬀects, but extensive research has not been conducted to conﬁrm the equal eﬃcacy of these drugs with
clozapine.
203“Treatment-resistant populations” includes those who have not adequately responded to conventional/typical antipsychotics.
The use of the atypical antipsychotics as a treatment for those populations is consistent with the FDA’s approval requirements.
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45decreases.”206
The incidence of schizophrenia itself, left untreated, translates into excessive poverty, due to the under- and
unemployment of these patients, further making these individuals dependent on government assistance.207
Passage of health care reform bills such as the Medicare Mental Health Modernization Act may “ensure that
Medicare beneﬁciaries with severe mental illnesses are able to access non-discriminatory coverage that will
allow them to work and reach their full potential.”208
Clozapine clearly presents a signiﬁcant health risk to the patients who attempt to beneﬁt from its use. Thus,
a conservative point of view regarding the United States’ health care resources may argue that the supply
of such hazardous drugs should not become a priority on the country’s health care agenda. Commentators
siding with this view may further argue that the government should divert needed resources elsewhere, where
the funds would provide much needed health care via other drugs and medical needs with more deﬁnite ben-
eﬁts to patients.
However, resources allocated toward provision of clozapine to patients would not be wasted. As the product
literature indicates, clozapine is not a treatment in danger of being overutilized by the medical community.
Its use is heavily monitored and any unnecessary treatments with the medication will promptly cease due to
the dangers associated with its use. Thus, clozapine comes with a built-in safeguard against over-distribution
of the drug. Only those who clearly beneﬁt from its use will obtain or continue to obtain the medication.209
In addition, the cost of clozapine may be lowered through increased competition with newer and more af-
206The Schizophrenia Homepage, supra note 2.
207Lehman, supra note 13.
208Shannon supra note 179.
209However, it is worth mentioning that a successful schizophrenia treatment drug reimbursement program may become a
“victim of its own success,” as demonstrated by North Carolina’s attempt to broaden access to the atypical antipsychotics
through a special fund set aside for the provision of atypical antipsychotics to schizophrenic patients in need. The program
became so successful in broadening access that the number of clients covered by the fund created a strain on the state’s resources.
Behavioral Health Business News, supra note 153. Thus, one opposing health care coverage of atypical antipsychotics may argue
that, although improving access to the drugs may reduce the cost of treatment of schizophrenia per patient, the number of
treatment-seeking patients may increase to such an extent that the overall cost of treating schizophrenics may indeed increase.
However, to argue that broadening access to such an extent that those in need will actually seek help represents a negative eﬀect
of providing mental health care coverage emphasizes the need to shut out all concerns excepting cost in making evaluations of
whether to provide coverage.
46fordable drugs (such as the injectable form of risperdal). Physicians treating their patients for schizophrenia
should have the freedom to select whichever of the atypical antipsychotics they feel is most appropriate for
the individual patient. “Each of the atypical antipsychotics has its niche with its own set of negative factors
attached to it, necessitating the ﬁne-tuning of each agent for each individual patient.”210
The need for providing medications with lasting eﬀects, thereby reducing the possibility of relapse is key
to both improving the quality of life for schizophrenics and in cutting costs due to repeat hospitalizations.
The American Psychiatric Association estimates that between 20 percent and 50 percent of people with
schizophrenia who are treated with medication are rehospitalized each year.211 Twenty percent of patients
who remain on medication will relapse within one year, while 70 percent of patients who discontinue their
medication will relapse within the same time period.212 One study estimates that patients taking Risperdal
take a signiﬁcantly longer time to relapse than those on haloperidol, a conventional antipsychotic that “was
long considered the gold standard for treatment of psychosis.”213
As technology rapidly evolves in the area of antipsychotic treatments, such as the injectable forms of the
atypical risperdal, which is currently awaiting FDA approval, in creating policy, there are several concerns
that must be balanced. Concern for patients’ access to needed medication and physician autonomy to pre-
scribe those medications is understandably of paramount concern.
The establishment of spending caps on drug therapy may further unnecessarily increase mental health care
costs. One study demonstrated that a monthly spending cap on the coverage for the cost of psychotropic
prescription drugs, including antipsychotics, “can increase the use of acute mental health services among
210Chernin, supra note 118 at 33.
211Schizophrenia: Risperdal Can Decrease Risk of Relapse in Long-Term Treatment Protocol, Drug Week 23 (February 1,
2002).
212AMA Council, supra note 130 at 22.
213Drug Week, supra note 211.
47low-income patients with chronic mental illnesses and increase costs to the government, even aside form
the increases caused in pain and suﬀering on the part of the patients.”214 The study demonstrated that
a cap on mental health coverage resulted in an immediate and sustained decrease in the amount of usage
of antipsychotics and other mental health treatments.215 “The resulting increase in agitation and in the
frequency of psychotic episodes would increase the need for emergency mental health services and partial
hospitalization (full-day or half-day treatment programs) at community mental health centers and the fre-
quency of admissions to psychiatric hospitals, thereby shifting costs form the federal-state Medicaid program
to state mental health programs.”216
Signiﬁcantly, even a small reduction in reimbursement for antipsychotic medications can result in “substan-
tial unintended eﬀects on low-income people with chronic mental illnesses.”217 The disruptions caused in
successful treatments or the exacerbation of mental illnesses such as schizophrenia may, in the short-term
result in cost reductions, but will lead to immediate or, at the very least, a long-term increase in the use of
acute mental health care services, which will result in an ultimate increase in the cost of health care.
Drug reimbursement caps due to the chronic nature of schizophrenia especially jeopardize the welfare of
schizophrenic patients. “Patients on maintenance drug therapy for chronic conditions are especially endan-
gered when access to pharmaceuticals is limited by a prescription cap. In one study of schizophrenic patients
on Medicaid, hospitalizations rose signiﬁcantly with the introduction or prescription caps.”218 Thus, argu-
214Stephen B. Soumerai, Thomas J. McLaughlin, et al., Eﬀects of Limiting Medicaid Drug-Reimbursement Beneﬁts on the
Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia, 331 New England J. of Med.
No. 10, 650-655 (1994).
215Id.
216Id. (There was an increase in the administration of anti-psychotic agents at the CMHCs, which are funded by the state
mental health systems.)
217Id.
218Managed Care Cost Containment Involving Prescription Drugs, 53 Food & Drug L. J. 25, 30 (1998), by American Medical
48ments that the provision of equitable coverage for the atypicals would raise the costs of health care to such an
extent that health care resources as a whole would become scarce is an empirically unsupported argument.
Indeed, the opposite seems to be true. The analysis accompanying the empirical results of studies such as
the one mentioned above suggests that, in the long-term, the population of schizophrenics, the institutions
that support the funding of their mental health care and society at large stand to beneﬁt from the provision
of access to the atypicals.
Conclusion
Atypical antipsychotic medications have revolutionized the treatment of schizophrenia. Schizophrenic indi-
viduals have the ability to overcome their cognitive dysfunction and anti-social behavior through the use
of these drugs, making their lives more complete and fulﬁlling, while alleviating pressure placed on medical
resources in hospitals and other in-patient care facilities.
Members of the schizophrenic community, as part of the larger community of mentally ill individuals, through
their experience in seeking suﬃcient resources for the treatment of their disorder, have illustrated the diﬃcul-
ties faced by the mentally ill in securing funding for health care. Due to the greater awareness of the nature
of schizophrenia and other severe mental illnesses (particularly those with a physiological basis), regulation
by federal and state governments should provide for the equitable treatment of these illnesses as compared to
their “wholly physiological” counterparts. Though progress appears slow and uncertain, the rising education
about the nature of mental illness generally will hopefully lead to the progressive legislation that will ensure
the coverage of these necessary treatments for schizophrenia.
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